Endpoints News 14. Apr. 2026 Revolution Medicines leads latest wave of stock offerings, totaling $1.5B
Endpoints News 14. Apr. 2026 J&J increasingly confident it can manage Stelara cliff, but work remains
Endpoints News 14. Apr. 2026 Parker Institute doubles down on cancer vaccines as part of ongoing reboot
Endpoints News 14. Apr. 2026 FDA approves Travere's Filspari as first drug for the kidney disease FSGS
Endpoints News 13. Apr. 2026 White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says
Endpoints News 13. Apr. 2026 Neomorph raises $100M for molecular glues; Spyre's ulcerative colitis data
Endpoints News 13. Apr. 2026 Revolution Medicines' pancreatic cancer drug doubles survival time in Phase 3
Endpoints News 13. Apr. 2026 Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial